Ignite Creation Date:
2025-12-24 @ 12:43 PM
Ignite Modification Date:
2026-04-17 @ 12:13 PM
Study NCT ID:
NCT01998061
Status:
UNKNOWN
Last Update Posted:
2013-12-20
First Post:
2013-11-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression
Sponsor:
Zhejiang University
Organization:
Study Overview
Official Title:
Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
UNKNOWN
Status Verified Date:
2013-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There have been reports suggesting that continuous administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is advantageous for patients in which gradual disease progression was observed after the establishment of clinical benefit from EGFR-TKIs. However, whether EGFR TKI with or without chemotherapy provides more survival benefit has not been formally evaluated.
Detailed Description:
We design this clinical trial to compare the efficacy of continuation of EGFR TKI with or without chemotherapy in patients beyond gradual progression.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: